But still, the response rate to programmed cell death protein 1 (PD1) inhibitors, such as nivolumab and pembrolizumab, is only 30%–45% in dMMR/MSI-H colorectal cancer [4–6]. Here, PDCD1 is linked to colorectal cancer.